Upload
PPT-Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug

PPT-Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug

Author : megan | Published Date : 2024-02-09

Shah N Richardson J Moodley P Moodley S Babaria P Ramtahal M et al Increasing Drug Resistance in Extensively DrugResistant Tuberculosis South Africa Emerg Infect

resistant drug drug resistant moodley tuberculosis resistance extensively south

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Figure 2 Figure 2. Determinatio..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug: Transcript

Download Document

Here is the link to download the presentation.
"Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations
Figure 4 Figure 4. Control measures for bovine tuberculosis based on test-and-slaughter

Figure 4 Figure 4. Control measures for bovine tuberculosis based on test-and-slaughter
Figure 1 Figure 1. Global incidence of tuberculosis. Of the estimated 8.8 million

Figure 1 Figure 1. Global incidence of tuberculosis. Of the estimated 8.8 million
Figure 1 Figure 1. Distribution of tuberculosis cases reported to health authorities

Figure 1 Figure 1. Distribution of tuberculosis cases reported to health authorities
Figure 1 Figure 1. Colony morphology on Löwenstein-Jensen slants, showing M.

Figure 1 Figure 1. Colony morphology on Löwenstein-Jensen slants, showing M.
Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,
Figure 3 Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative

Figure 3 Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative
Figure 1 Figure 1. Mycobacterium tuberculosis complex lineages as determined

Figure 1 Figure 1. Mycobacterium tuberculosis complex lineages as determined
Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient

Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient
Figure 2 Figure 2. Epidemologic links among tuberculosis patients, Arkansas,

Figure 2 Figure 2. Epidemologic links among tuberculosis patients, Arkansas,
Figure Figure. Chest radiograph of a tuberculosis patient addicted to crack cocaine.

Figure Figure. Chest radiograph of a tuberculosis patient addicted to crack cocaine.
Figure 3 Figure 3. ART use and TB prevalence in HIV-infected children and adolescents,

Figure 3 Figure 3. ART use and TB prevalence in HIV-infected children and adolescents,
Figure 1 Figure 1. Summary of published aggregate data on the prevalence of pneumococci

Figure 1 Figure 1. Summary of published aggregate data on the prevalence of pneumococci